Cargando…
Chemotherapy and radiation for prostate cancer
Over the past few decades there is growing appreciation for the role of chemotherapy in treatment of prostate cancer. Initial successful phase III randomized trials in castration resistant prostate cancer (CRPC) have led to additional successful trials in earlier presentations of disease. Given the...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043747/ https://www.ncbi.nlm.nih.gov/pubmed/30050799 http://dx.doi.org/10.21037/tau.2018.03.07 |
_version_ | 1783339347939950592 |
---|---|
author | Hurwitz, Mark David |
author_facet | Hurwitz, Mark David |
author_sort | Hurwitz, Mark David |
collection | PubMed |
description | Over the past few decades there is growing appreciation for the role of chemotherapy in treatment of prostate cancer. Initial successful phase III randomized trials in castration resistant prostate cancer (CRPC) have led to additional successful trials in earlier presentations of disease. Given the established role of radiation in management of locally advanced disease and demonstrated efficacy of taxanes in treatment of prostate cancer, optimal combination of radiation and chemotherapy in this patient population has garnered increased attention. Successful phase III trials in this space have given additional stimulus to further exploring combination therapy with radiation. New directions include assessment of additional chemotherapeutic agents including cabazitaxel and PARP inhibitors as well as personalization of therapy with use of genomic testing and other emerging markers to guide therapeutic decisions. |
format | Online Article Text |
id | pubmed-6043747 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-60437472018-07-26 Chemotherapy and radiation for prostate cancer Hurwitz, Mark David Transl Androl Urol Review Article Over the past few decades there is growing appreciation for the role of chemotherapy in treatment of prostate cancer. Initial successful phase III randomized trials in castration resistant prostate cancer (CRPC) have led to additional successful trials in earlier presentations of disease. Given the established role of radiation in management of locally advanced disease and demonstrated efficacy of taxanes in treatment of prostate cancer, optimal combination of radiation and chemotherapy in this patient population has garnered increased attention. Successful phase III trials in this space have given additional stimulus to further exploring combination therapy with radiation. New directions include assessment of additional chemotherapeutic agents including cabazitaxel and PARP inhibitors as well as personalization of therapy with use of genomic testing and other emerging markers to guide therapeutic decisions. AME Publishing Company 2018-06 /pmc/articles/PMC6043747/ /pubmed/30050799 http://dx.doi.org/10.21037/tau.2018.03.07 Text en 2018 Translational Andrology and Urology. All rights reserved. |
spellingShingle | Review Article Hurwitz, Mark David Chemotherapy and radiation for prostate cancer |
title | Chemotherapy and radiation for prostate cancer |
title_full | Chemotherapy and radiation for prostate cancer |
title_fullStr | Chemotherapy and radiation for prostate cancer |
title_full_unstemmed | Chemotherapy and radiation for prostate cancer |
title_short | Chemotherapy and radiation for prostate cancer |
title_sort | chemotherapy and radiation for prostate cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043747/ https://www.ncbi.nlm.nih.gov/pubmed/30050799 http://dx.doi.org/10.21037/tau.2018.03.07 |
work_keys_str_mv | AT hurwitzmarkdavid chemotherapyandradiationforprostatecancer |